Biotech Stocks Reach Post-Pandemic High Following Moderna's Trial Success
Biotech stocks have climbed to a post-pandemic high after Moderna and Merck announced positive results from a late-stage trial of their mRNA-based cancer therapy. The treatment met its primary endpoints, boosting investor confidence in the sector. The success marks a significant milestone for RNA technology beyond vaccines into oncology applications. Healthcare emerged as the top-performing sector on the day due to these developments.
